On April 6, 2011 was published in PloS One a fascinating study in which, once again demonstrates the power of the chemical-pharmaceutical industry. In analysis, incidentally, laboratory studies give a 0% ratio AD (antidepressants) / breast or ovarian cancer, while studies from independent laboratories, the percentage is over 43% . Almost nothing!. The study was conducted by Edmond J. Center Safra for Ethics at Harvard University . According to him, over 60% of researchers working for pharmaceutical companies and found no association between antidepressants and cancer . seems that after this the researchers propose the use of antidepressants included in the protocol breast cancer screening and the informed consent (good thing). In this ties of Farmaindustria, speaks at length Miguel Jara in his book "Dealers of Health." PLoS One 6 April 2011, 6 (4): e18210. Antidepressants and the risk of breast cancer and ovarian cancer: A review of the literature and financial partnerships with industry researchers. L Cosgrove, Shi L, DE Creasey, McKivergan M-Anaya, JA Myers, Huybrechts KF. Center Edmond J. Safra for Ethics at Harvard University, Cambridge, Massachusetts, USA.
Summary
Summary
BACKGROUND: The use of antidepressants (AD) has been suggested that increase the risk of breast cancer and ovarian cancer, although in pre-clinical and epidemiological studies, both have reported conflicting results [1 ] - [6]. Previous studies in various fields of biomedicine have found that financial ties with pharmaceutical companies associated with the study's conclusions favorable [7].
METHODS AND RESULTS: We searched English language articles on MEDLINE, PsychINFO, the Index of Scientific Citations and the Registry Cochrane Central Controlled Trials (to November 2010). A total of 61 articles that assessed the association between breast cancer and ovarian cancer and the use of AD and articles that examined the effect of ads on cell growth were included. Modal multi-screening techniques were used to investigate researchers' financial ties with industry. A meta-analysis was used random effects to share the findings of the epidemiological literature. Thirty-three percent (20/61) of the studies reported a positive association between AD and cancer . Sixty-seven percent (41/61) of studies reported no association or antiproliferative effect. The pooled odds ratio for the association between use of AD and breast / ovarian cancer in epidemiological studies was 1.11 (95% CI 1.03-1.20). Researchers industry affiliations were significantly less likely than researchers without ties to the conclusion that AD increase the risk of breast or ovarian . ( 0 / 15 [0%] versus 20/46 [43.5%] (Fisher exact test, P = 0.0012).
CONCLUSIONS: Both clinical and Previous clinical data are mixed in terms of showing an association between use of AD and breast cancer and ovarian cancer. The possibility that the ads can show bi-phasic effect on the short-term use and / or low-dose antidepressants may increase the risk of breast cancer and ovarian cancer, warrants further investigation. industry affiliations were associated with negative findings on cancer risk . The results have implications in the light of the 2009 Guidelines for the USPSTF breast cancer screening and informed consent process . PMID: 21494667 [PubMed - as supplied by publisher] access to the original publication (in English ).
METHODS AND RESULTS: We searched English language articles on MEDLINE, PsychINFO, the Index of Scientific Citations and the Registry Cochrane Central Controlled Trials (to November 2010). A total of 61 articles that assessed the association between breast cancer and ovarian cancer and the use of AD and articles that examined the effect of ads on cell growth were included. Modal multi-screening techniques were used to investigate researchers' financial ties with industry. A meta-analysis was used random effects to share the findings of the epidemiological literature. Thirty-three percent (20/61) of the studies reported a positive association between AD and cancer . Sixty-seven percent (41/61) of studies reported no association or antiproliferative effect. The pooled odds ratio for the association between use of AD and breast / ovarian cancer in epidemiological studies was 1.11 (95% CI 1.03-1.20). Researchers industry affiliations were significantly less likely than researchers without ties to the conclusion that AD increase the risk of breast or ovarian . ( 0 / 15 [0%] versus 20/46 [43.5%] (Fisher exact test, P = 0.0012).
CONCLUSIONS: Both clinical and Previous clinical data are mixed in terms of showing an association between use of AD and breast cancer and ovarian cancer. The possibility that the ads can show bi-phasic effect on the short-term use and / or low-dose antidepressants may increase the risk of breast cancer and ovarian cancer, warrants further investigation. industry affiliations were associated with negative findings on cancer risk . The results have implications in the light of the 2009 Guidelines for the USPSTF breast cancer screening and informed consent process . PMID: 21494667 [PubMed - as supplied by publisher] access to the original publication (in English ).
0 comments:
Post a Comment